S3-E18.2 – Previewing Innovations in NAFLD Care 2022: NASH Epidemiology
Learn about the rationale and focus for Sessions 1 and 2 of the Innovations in NAFLD Care Workshop and NASH epidemiology for action.
April 9, 2022
Learn about the rationale and focus for Sessions 1 and 2 of the Innovations in NAFLD Care Workshop and NASH epidemiology for action.
Learn about the history and interests that led Professors Jeff Lazarus and Jörn Schattenberg to launch the Innovations in NAFLD Care 2022 Workshop
Which riddles around hepatic regeneration can we foresee answering in the future as the capabilities around single-cell genomics and its successors continue to expand rapidly?
This episode focuses on the history of single-cell genomics up through spatial transcriptomics and beyond and raises questions about the new things we can learn and the demand these improved techniques place on other elements in the research process.
What are the implications of the targeted NASH therapies of the future on NASH drug development today?
What do recent findings in mRNA/CAR-T anti-fibrotic therapies and advanced NASH omics promise for the future of treating NAFLD and NASH?
This episode is Sponsored by Resoundant.
What are the practical benefits and challenges for clinicians wishing to deploy MRE (through MAST and/or Hepatogram along with PDFF) as an outpatient test in NASH Clinical Practice?
This episode is Sponsored by Resoundant.
What can a NASH Disease Model tell us about the value of FIB-4 in the NASH Diagnostic Pathway vs. more expensive tests with stronger predictive values, both today and as other NITs improve?
This episode is Sponsored by Resoundant.
Panelists explore several key questions that have arisen at recent meetings like Liver Connect, including the value of waist circumference measurements, the interplay of NAFLD and alcohol consumption and the definition of a “fast progressor.”
This episode is Sponsored by Resoundant.
What can a NASH disease model teach us about treating patients with Advanced Fibrosis (F2/F3) in terms of the economic and medical rationales for therapy and optimal approaches?